Heron Therapeutics (HRTX) Q2 2024 earnings summary

Executive summary

• Net product sales reached $36.0 million in Q2 2024, up from $31.8 million in Q2 2023, driven by increased sales across all product lines and operational improvements.

• New management provided updated financial guidance, narrowing adjusted operating expenses and adjusted EBITDA.

• ZYNRELEF VAN device PDUFA goal date set for September 23, 2024, with launch expected before year-end.

• ZYNRELEF included in proposed 2025 NOPAIN Act, supporting continued reimbursement and expanded market opportunity.

• CrossLink sales force integration progressing, with 561 representatives trained and targeting 650+ by VAN launch.

Financial highlights

• Q2 2024 net product sales: $36.0M, up from $31.8M in Q2 2023; YTD sales: $70.7M, up from $61.4M.

• Gross profit for Q2 2024: $25.5M (70.8%), up from $11.6M (63.6%) in Q2 2023.

• Net loss for Q2 2024: $9.2M ($0.06 per share), improved from $42.1M ($0.35 per share) in Q2 2023.

• Cash and short-term investments totaled $67.3M as of June 30, 2024.

• Operating expenses for Q2 2024: R&D $4.4M, SG&A $27.5M, all down year-over-year.

Outlook and guidance

• 2024 net product revenue guidance: $138M–$158M.

• Adjusted operating expenses guidance narrowed to $107M–$111M.

• Adjusted EBITDA guidance for 2024: $(10)M to $3M.

• Gross margin expected to remain in the low-to-mid 70% range.

• Current cash and investments expected to fund operations for at least 12 months.